Navigation Links
BioMarin to Host Fourth Quarter and Full Year 2007 Financial Results Conference Call and Webcast on Tuesday, February 26 at 5:00 p.m. ET (23:00 CET)
Date:2/5/2008

NOVATO, Calif., Feb. 5 /PRNewswire-FirstCall/ -- BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) today announced that Jean-Jacques Bienaime, Chief Executive Officer of BioMarin, will host a conference call and webcast on Tuesday, February 26, at 5:00 p.m. ET (23:00 CET) to discuss fourth quarter and full year 2007 financial results.

U.S. / Canada Dial-in Number: 866.713.8564

International Dial-in Number: 617.597.5312

Participant Code: 79434433

Replay Dial-in Number: 888.286.8010

Replay International Dial-in Number: 617.801.6888

Replay Code: 87203261

Interested parties may access a live audio webcast of the conference call via the investor section of the BioMarin website, http://www.BMRN.com. A replay of the call will be archived on the site for at least one week following the call.

About BioMarin

BioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. The company's product portfolio comprises three approved products and multiple clinical and preclinical product candidates. Approved products include Naglazyme(R) (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin; Aldurazyme(R) (laronidase) for mucopolysaccharidosis I (MPS I), a product which BioMarin developed through a 50/50 joint venture with Genzyme Corporation; and Kuvan(TM) (sapropterin dihydrochloride) Tablets, a product for the treatment of phenylketonuria (PKU), developed in partnership with Merck Serono, a division of Merck KGaA of Darmstadt, Germany. Other product candidates include 6R-BH4 for cardiovascular indications, which is currently in Phase 2 clinical development for the treatment of peripheral arterial disease and sickle cell disease, and PEG-PAL (PEGylated recombinant phenylalanine ammonia lyase) for the treatment of PKU. For additional information, please visit http://www.BMRN.com. Information on BioMarin's website is not incorporated by reference into this press release.

BioMarin(R) and Naglazyme(R) are registered trademarks of BioMarin Pharmaceutical Inc.

Aldurazyme(R) is a registered trademark of BioMarin/Genzyme LLC.

Contacts:

Investors Media

Eugenia Shen Susan Berg

BioMarin Pharmaceutical Inc. BioMarin Pharmaceutical Inc.

(415) 506-6570 (415) 506-6594


'/>"/>
SOURCE BioMarin Pharmaceutical Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. BioMarin to Present at the Bear Stearns 20th Annual Healthcare Conference
2. BioMarin Provides Grant to NORD to Expand PKU Patient Support Services
3. BioMarin Re-Acquires Rights to Kuvan in Canada From Merck Serono
4. Fairview Specialty Pharmacy Signs Contract With BioMarin for Distribution of Kuvan(TM)
5. One-fourth of HIV patients believe their doctors stigmatize them
6. Memry Corporation Announces Fiscal Fourth Quarter and 2007 Year End Earnings Release and Conference Call
7. Authentidate Holding Corp. to Report Fourth Quarter and Fiscal 2007 Year End Results on Thursday, September 13, 2007
8. Hillenbrand Industries Announces Fourth Quarter 2007 Dividend
9. Allied Healthcare Reports Strong Fourth Quarter, Flat Net Income for Fiscal 2007 vs. 2006
10. Robbins & Myers to Release Fourth Quarter and 2007 Fiscal Year Results on Monday, October 15, 2007
11. NMHC Reports Fourth Quarter and Fiscal Year 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... ... ... Students interested in video can get a jump start on their education ... $1,000 scholarship and have his or her video posted on the GenCure website and ... with the winner announced on June 9. , The competition is designed to help ...
(Date:1/19/2017)... ... January 19, 2017 , ... Sam & Associates Insurance Agency, a full ... clients in the California Bay Area, is launching a charity drive to raise awareness ... Heart disease is the primary killer of adult men and women in America, and ...
(Date:1/19/2017)... ... January 19, 2017 , ... Attorney Robert “RC” ... consecutive year donated money to the Triumph Over Kid Cancer foundation. Each year, 175,000 ... of those children. James saw firsthand the effect of the critical funding gap for ...
(Date:1/19/2017)... ... January 19, 2017 , ... Connecticut Dermatology Group (CDG) is proud and excited ... compassionate dermatologist. Dr. Kim brings an extensive background in cutting-edge dermatology care and ... pleasure to welcome back Dr. Kim to the CDG team” said President and Managing ...
(Date:1/19/2017)... ... January 19, 2017 , ... Each ... Surgery Symposium, a conference where hundreds of surgeons from over fifteen different countries ... topics from cosmetic breast augmentation to breast reconstruction for breast cancer ...
Breaking Medicine News(10 mins):
(Date:1/18/2017)... -- Research and Markets has announced the addition of the ... Global Opportunity Analysis and Industry Forecast, 2014-2022" report to their offering. ... Vital signs monitoring market ... $5,491 million by 2022, growing at a CAGR of 5.8% from 2016 ... the leading regional market in global vital signs monitoring devices industry. The ...
(Date:1/18/2017)... Jan. 18, 2017  Adaptive Sound Technologies, Inc. (ASTI), the ... partnership with Hyatt Place Nashville/Downtown to deliver the best ... sleep therapy machines in over two hundred of its ... important parts of having a great stay is sleeping ... Hyatt Place Nashville/Downtown. "We,re pleased to be able to ...
(Date:1/18/2017)... , Jan. 18, 2017   Regenicin, Inc. ... biotechnology company specializing in the development and commercialization of ... tissues and organs, recently reported the Company,s operating results ... 2017. As the Company described in its ... a year of substantial accomplishments. The Company,s contract laboratory ...
Breaking Medicine Technology: